Roche Secures FDA Approval for Tecentriq-Based Immunotherapy in Stage III Colon Cancer
Pharm'Up 
The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of adult patients with stage III deficient mismatch repair (dMMR) colon cancer[cite: 1]. This decision marks the first FDA-approved adjuvant immunotherapy regimen for this specific patient population following surgery[cite: 2].
Key Clinical Trial Data (ATOMIC Study)
The approval is supported by positive results from the Phase III ATOMIC trial, which randomized 712 patients to receive either Tecentriq plus modified FOLFOX6 chemotherapy or chemotherapy alone[cite: 3].
- Risk Reduction: The addition of Tecentriq to chemotherapy demonstrated a 50% reduction in the risk of disease recurrence or death compared to chemotherapy alone[cite: 4].
- Disease-Free Survival (DFS): At 36 months, the DFS rate was 86% for patients receiving the Tecentriq combination, compared to 76% for those receiving chemotherapy alone[cite: 5].
Treatment Regimen and Biomarker Rationale
In the trial, the combination group received modified FOLFOX6 and Tecentriq for 12 cycles (6 months), followed by Tecentriq monotherapy for an additional 13 cycles (6 months)[cite: 6]. The control group received 12 cycles of modified FOLFOX6 alone[cite: 7].
This immunotherapy regimen is specifically indicated for patients whose tumors are identified as dMMR, a biomarker associated with impaired DNA repair and increased mutation rates[cite: 8]. Roche estimates that approximately 15% of colon cancer patients have dMMR tumors, which may be particularly responsive to immunotherapy[cite: 9].
About the Author
